A Phase 1/2 Study of Selinexor in Combination With Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma
Latest Information Update: 18 Dec 2024
At a glance
- Drugs Selinexor (Primary) ; Bevacizumab; Carmustine; Lomustine; Temozolomide
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms KING
- Sponsors Karyopharm Therapeutics
Most Recent Events
- 31 Aug 2023 Protocol has been amended as above-1) treatment arms has been changed from 10 to 8. 2)Recruitment status has been terminated. 3) actual number of patients has been changed to 74
- 31 Aug 2023 Status changed from active, no longer recruiting to discontinued.
- 11 Jul 2023 Planned End Date changed from 1 Apr 2024 to 1 Jul 2023.